{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:39:05Z","timestamp":1794004745226,"version":"4.8.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.beem.2024.101907","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:02:43Z","timestamp":1719385363000},"page":"101907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Metabolic and cardiovascular risks of hormone treatment for transgender individuals"],"prefix":"10.1016","volume":"38","author":[{"given":"Nipun Lakshitha","family":"de Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Dimakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Quinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channa N.","family":"Jayasena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"sup1","key":"10.1016\/j.beem.2024.101907_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, version 8","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J Transgender Health"},{"key":"10.1016\/j.beem.2024.101907_bib2","article-title":"Cardiovascular disease and feminizing gender-affirming hormone therapy: Implications for the provision of safe and lifesaving care","volume":"33","author":"Pribish","year":"2023","journal-title":"Curr Opin Physiol"},{"issue":"1","key":"10.1016\/j.beem.2024.101907_bib3","first-page":"42","article-title":"Prevalence and predictors of cardiovascular disease and risk factors in transgender persons in the United States","volume":"21","author":"Malhotra","year":"2022","journal-title":"Crit Pathw Cardiol"},{"issue":"6","key":"10.1016\/j.beem.2024.101907_bib4","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1161\/CIR.0000000000001003","article-title":"Assessing and addressing cardiovascular health in people who are transgender and gender diverse: a scientific statement from the American Heart Association","volume":"144","author":"Streed","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.beem.2024.101907_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00021.2015","article-title":"Mechanistic pathways of sex differences in cardiovascular disease","volume":"97","author":"Regitz-Zagrosek","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1016\/j.beem.2024.101907_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5992","article-title":"Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study","volume":"349","author":"Leening","year":"2014","journal-title":"Bmj"},{"issue":"11","key":"10.1016\/j.beem.2024.101907_bib7","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1210\/jc.2017-01643","article-title":"Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis","volume":"102","author":"Maraka","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2024.101907_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacl.2022.11.010","article-title":"Lipid profiles and hypertriglyceridemia among transgender and gender diverse adults on gender-affirming hormone therapy","volume":"17","author":"Leemaqz","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.beem.2024.101907_bib9","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1210\/jc.2018-02138","article-title":"Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen","volume":"104","author":"van Velzen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2024.101907_bib10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jsxm.2021.01.185","article-title":"Does gender-affirming hormonal treatment affect 30-year cardiovascular risk in transgender persons? A two-year prospective European Study (ENIGI)","volume":"18","author":"Cocchetti","year":"2021","journal-title":"J Sex Med"},{"issue":"3","key":"10.1016\/j.beem.2024.101907_bib11","doi-asserted-by":"crossref","first-page":"H522","DOI":"10.1152\/ajpheart.00346.2023","article-title":"Proposed mechanisms of hypertension and risk of adverse cardiovascular outcomes in LGBT communities","volume":"325","author":"Taweh","year":"2023","journal-title":"Am J Physiol-Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.beem.2024.101907_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2265.2009.03632.x","article-title":"Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta\u2010analyses","volume":"72","author":"Elamin","year":"2010","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2024.101907_bib13","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/HYPERTENSIONAHA.120.16839","article-title":"Blood pressure effects of gender-affirming hormone therapy in transgender and gender-diverse adults","volume":"77","author":"Banks","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.beem.2024.101907_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41440-022-01067-z","article-title":"Incidence of hypertension in young transgender people after a 5-year follow-up: association with gender-affirming hormonal therapy","volume":"46","author":"Martinez-Martin","year":"2023","journal-title":"Hypertens Res"},{"issue":"5","key":"10.1016\/j.beem.2024.101907_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/and.12660","article-title":"Cross\u2010sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta\u2010analysis","volume":"49","author":"Klaver","year":"2017","journal-title":"Andrologia"},{"issue":"12","key":"10.1016\/j.beem.2024.101907_bib16","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1038\/s41366-021-00935-x","article-title":"Weight gain and obesity rates in transgender and gender-diverse adults before and during hormone therapy","volume":"45","author":"Kyinn","year":"2021","journal-title":"Int J Obes"},{"issue":"3","key":"10.1016\/j.beem.2024.101907_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4239\/wjd.v11.i3.66","article-title":"Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review","volume":"11","author":"Spanos","year":"2020","journal-title":"World J Diabetes"},{"issue":"1","key":"10.1016\/j.beem.2024.101907_bib18","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1210\/clinem\/dgab616","article-title":"Change in visceral fat and total body fat and the effect on cardiometabolic risk factors during transgender hormone therapy","volume":"107","author":"Klaver","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2024.101907_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2337\/dc19-1061","article-title":"Effects of gender-affirming hormone therapy on insulin sensitivity and incretin responses in transgender people","volume":"43","author":"Shadid","year":"2020","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.beem.2024.101907_bib20","doi-asserted-by":"crossref","first-page":"e2000","DOI":"10.1210\/clinem\/dgab934","article-title":"Incident diabetes risk is not increased in transgender individuals using hormone therapy","volume":"107","author":"van Velzen","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2024.101907_bib21","doi-asserted-by":"crossref","first-page":"e1549","DOI":"10.1210\/clinem\/dgab832","article-title":"Is there a link between hormone use and diabetes incidence in transgender people? Data from the STRONG cohort","volume":"107","author":"Islam","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2024.101907_bib22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2265.1997.2601068.x","article-title":"Mortality and morbidity in transsexual subjects treated with cross-sex hormones","volume":"47","author":"van Kesteren","year":"1997","journal-title":"Clin Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2024.101907_bib23","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/CIRCULATIONAHA.118.038584","article-title":"Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy","volume":"139","author":"Nota","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.beem.2024.101907_bib24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S2213-8587(21)00185-6","article-title":"Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria","volume":"9","author":"de Blok","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2024.101907_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M17-2785","article-title":"Cross-sex hormones and acute cardiovascular events in transgender persons: A Cohort Study","volume":"169","author":"Getahun","year":"2018","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.beem.2024.101907_bib26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1530\/EJE-13-0493","article-title":"Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case\u2013control study","volume":"169","author":"Wierckx","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101907_bib27","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad388","article-title":"Testosterone replacement therapy in relation with cardiovascular disease in cisgender women and transgender people","author":"Lopez","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2024.101907_bib28","article-title":"Cardiovascular disease risk factors and myocardial infarction in the transgender population","volume":"12","author":"Alzahrani","year":"2019","journal-title":"Circ: Cardiovasc Qual Outcomes"},{"issue":"3","key":"10.1016\/j.beem.2024.101907_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1530\/EJE-22-0306","article-title":"Cardiovascular risk in Danish transgender persons: a matched historical cohort study","volume":"187","author":"Glintborg","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2024.101907_bib30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-10-1038","article-title":"A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones","volume":"164","author":"Asscheman","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2024.101907_bib31","first-page":"498","article-title":"The effect of gender-affirming hormone therapy on the risk of subclinical atherosclerosis in the transgender population: a systematic review","volume":"29","author":"Moreira Allgayer","year":"2023","journal-title":"Endocr Pr J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2024.101907_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.fertnstert.2020.08.002","article-title":"Testosterone administration increases leukocyte-endothelium interactions and inflammation in transgender men","volume":"115","author":"Iannantuoni","year":"2021","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.beem.2024.101907_bib33","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad040","article-title":"Arterial stiffness in transgender men receiving long-term testosterone therapy","volume":"7","author":"Cunha","year":"2023","journal-title":"J Endocr Soc"},{"issue":"6","key":"10.1016\/j.beem.2024.101907_bib34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-20-0370","article-title":"A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen","volume":"183","author":"Gava","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2024.101907_bib35","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jsxm.2016.09.012","article-title":"Differential effects of cyproterone acetate vs spironolactone on serum high-density lipoprotein and prolactin concentrations in the hormonal treatment of transgender women","volume":"13","author":"Fung","year":"2016","journal-title":"J Sex Med"},{"issue":"5","key":"10.1016\/j.beem.2024.101907_bib36","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2265.2003.01753.x","article-title":"Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects","volume":"58","author":"Elbers","year":"2003","journal-title":"Clin Endocrinol"},{"issue":"8","key":"10.1016\/j.beem.2024.101907_bib37","first-page":"883","article-title":"Differential endocrine and metabolic effects of testosterone suppressive agents in transgender women","volume":"26","author":"Sofer","year":"2020","journal-title":"Endocr Pr J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2024.101907_bib38","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1210\/jc.2017-01559","article-title":"Effects of sex hormone treatment on the metabolic syndrome in transgender individuals: focus on metabolic cytokines","volume":"103","author":"Auer","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2024.101907_bib39","doi-asserted-by":"crossref","first-page":"H861","DOI":"10.1152\/ajpheart.00299.2022","article-title":"Gender-affirming estrogen therapy route of administration and cardiovascular risk: a systematic review and narrative synthesis","volume":"323","author":"Turino Miranda","year":"2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"10.1016\/j.beem.2024.101907_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/humupd\/dmy039","article-title":"The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review","volume":"25","author":"Oliver-Williams","year":"2019","journal-title":"Hum Reprod Update"},{"issue":"5","key":"10.1016\/j.beem.2024.101907_bib41","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1210\/clinem\/dgab042","article-title":"Menopausal hormone therapy and cardiovascular disease: the role of formulation, dose, and route of delivery","volume":"106","author":"Shufelt","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2024.101907_bib42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1373\/clinchem.2018.288316","article-title":"Venous thrombotic risk in transgender women undergoing estrogen therapy: a systematic review and metaanalysis","volume":"65","author":"Khan","year":"2019","journal-title":"Clin Chem"},{"issue":"12","key":"10.1016\/j.beem.2024.101907_bib43","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1210\/jc.2003-030520","article-title":"Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people","volume":"88","author":"Toorians","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.beem.2024.101907_bib44","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1210\/jc.2012-2030","article-title":"Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens","volume":"97","author":"Seal","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.beem.2024.101907_bib45","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/and.12150","article-title":"Venous thrombo\u2010embolism as a complication of cross\u2010sex hormone treatment of male\u2010to\u2010female transsexual subjects: a review","volume":"46","author":"Asscheman","year":"2014","journal-title":"Andrologia"},{"issue":"25","key":"10.1016\/j.beem.2024.101907_bib46","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMcp1903650","article-title":"Care of transgender persons","volume":"381","author":"Safer","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beem.2024.101907_bib47","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2666-7568(22)00096-4","article-title":"Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis","volume":"3","author":"Hudson","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.beem.2024.101907_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular Safety of Testosterone-Replacement Therapy","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2024.101907_bib49","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.11887.1","article-title":"Spironolactone in cardiovascular disease: an expanding universe?","volume":"6","author":"Funder","year":"2017","journal-title":"F1000Research"},{"key":"10.1016\/j.beem.2024.101907_bib50","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes-2020","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2024.101907_bib51","unstructured":"NICE. Lipid modification- CVD prevention. National Institute for Health and Care Excellence. 2023."},{"key":"10.1016\/j.beem.2024.101907_bib52","unstructured":"UCSF Gender Affirming Health Program DoFaCM, University of California San Francisco. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. 2016."},{"key":"10.1016\/j.beem.2024.101907_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01542305","article-title":"Endocrine evaluation of forty female-to-male transsexuals: increased frequency of polycystic ovarian disease in female transsexualism","volume":"15","author":"Futterweit","year":"1986","journal-title":"Arch Sex Behav"},{"issue":"5","key":"10.1016\/j.beem.2024.101907_bib54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0306-4530(97)00033-4","article-title":"A higher rate of hyperandrogenic disorders in female-to-male transsexuals","volume":"22","author":"Bosinski","year":"1997","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"10.1016\/j.beem.2024.101907_bib55","first-page":"529","article-title":"Focus: Sex & reproduction: polycystic ovary syndrome and gender identity","volume":"93","author":"Liu","year":"2020","journal-title":"Yale J Biol Med"},{"issue":"9","key":"10.1016\/j.beem.2024.101907_bib56","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.jsxm.2020.05.029","article-title":"Ovarian histopathology in transmasculine persons on testosterone: a multicenter case series","volume":"17","author":"Grimstad","year":"2020","journal-title":"J Sex Med"},{"issue":"4","key":"10.1016\/j.beem.2024.101907_bib57","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.fertnstert.2008.12.017","article-title":"Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy","volume":"93","author":"Ott","year":"2010","journal-title":"Fertil Steril"},{"issue":"11","key":"10.1016\/j.beem.2024.101907_bib58","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jth.14626","article-title":"Transgender patients and the role of the coagulation clinician","volume":"17","author":"Connors","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.beem.2024.101907_bib59","doi-asserted-by":"crossref","DOI":"10.18332\/tpc\/114513","article-title":"Comparing smoking behavior between female-to-male and male-to-female transgender adults","volume":"6","author":"Tam\u00ed-Maury","year":"2020","journal-title":"Tob Prev Cessat"},{"issue":"1","key":"10.1016\/j.beem.2024.101907_bib60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4158\/EP161438.OR","article-title":"Increased rates of smoking cessation observed among transgender women receiving hormone treatment","volume":"23","author":"Myers","year":"2017","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.beem.2024.101907_bib61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1123\/jpah.2017-0298","article-title":"The levels and predictors of physical activity engagement within the treatment-seeking transgender population: a matched Control Study","volume":"15","author":"Jones","year":"2018","journal-title":"J Phys Act Health"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T09:44:14Z","timestamp":1728294254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24000617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1521690X24000617"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101907","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic and cardiovascular risks of hormone treatment for transgender individuals","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101907"}}